A senior research analyst at Piper Sandler believes Gilead Sciences Inc.'s (NASDAQ: GILD) Remdesivir antiviral may soon be approved for COVID-19 treatment.The Gilead Analyst Tyler Van Buren maintains a Neutral rating on Gilead with a price target of $70.The Gilead Thesis Remdesivir has been shown to be effective against COVID-19. Clinical data indicates Remdesivir is safer than alternative Favipiravir and also more effective. Van Buren said data gathered from 200 patients is "highly encouraging" and Remdesivir drug trials are positive.Trials conducted in China and Japan indicate that Favipiravir, which is manufactured by Toyama Chemical Co. owned by FUJIFILM Holdings Corp (OTC: FUJIY) under the brand name Avigan, also has efficacy against RNA viruses. The drug is somewhat effective in treating COVID-19, but needs to be used early on, according to Japanese officials.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our...
(Bloomberg) -- While for many U.S. restaurants it seems the sky is crashing down, Starbucks Corp. has a unique perspective after having gone through the same thing in China. Their chief executive officer’s message is this: If the strategy to contain coronavirus worked in China, it will work in North America too.“Our team in China defined elevated cleaning protocols for stores,” CEO Kevin Johnson told investors during a meeting with shareholders that was webcast for health reasons. “They basically created a model we are now using around the world, and we know that model worked.”The company now expects 95% of its China stores to be open in some form by the end of March. Currently 90% are open, although many are operating with reduced hours. For context, the virus began sparking widespread alarm and disrupting daily life in China in the second half of January.In the U.S., Starbucks is paying more...